IA
GALT icon

Inspire Advisors’s Galectin Therapeutics GALT Stock Holding History

Inspire Advisors’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$86.6K Sell
19,995
-1,100
-5% -$2.85K 0.01% 717
2026
Q1 		$58.9K Hold
21,095
– – ﹤0.01% 651
2025
Q4 		$87.8K Hold
21,095
– – 0.01% 541
2025
Q3 		$89.3K Hold
21,095
– – 0.01% 523
2025
Q2 		$44.5K Hold
21,095
– – ﹤0.01% 495
2025
Q1 		$25.7K Hold
21,095
– – ﹤0.01% 448
2024
Q4 		$27.2K Buy
21,095
+9,772
+86% +$23.4K ﹤0.01% 412
2024
Q3 		$31.1K Hold
11,323
– – ﹤0.01% 419
2024
Q2 		$25.6K Hold
11,323
– – ﹤0.01% 373
2024
Q1 		$27.1K Hold
11,323
– – ﹤0.01% 370
2023
Q4 		$18.8K Buy
+11,323
New +$22K ﹤0.01% 334

Other funds holding GALT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Inspire Advisors's GALT Position: Q2 2026 in Review

Inspire Advisors reduced its Galectin Therapeutics (GALT) stake by 5.2% in Q2 2026, selling an estimated $2.85K and leaving 19,995 shares worth $86.6K. The position accounts for 0.01% of the portfolio, ranked #717.

Inspire Advisors first reported a position in GALT in Q4 2023 and has held it in 11 quarters since. The position peaked at $89.3K in Q3 2025. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

  • Inspire Advisors held 19,995 shares of Galectin Therapeutics worth $86.6K as of Q2 2026.
  • Inspire Advisors sold 1,100 Galectin Therapeutics shares in Q2 2026, an estimated $2.85K.
  • Galectin Therapeutics made up 0.01% of Inspire Advisors's portfolio in Q2 2026, its #717 holding.
  • Inspire Advisors first reported a position in Galectin Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • Inspire Advisors's Galectin Therapeutics position peaked at $89.3K in Q3 2025.
  • 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on Inspire Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.